AP-1 Expression and its Clinical Relevance in Immune Disorders and Cancer

The American Journal of the Medical Sciences
Shivtia Trop-Steinberg, Yehudit Azar

Abstract

The inflammatory response is known to have a significant role in certain autoimmune diseases and malignancies. We review current knowledge regarding the functions of activator protein 1 (AP-1) as an important modulator in several immune disorders and carcinomas. AP-1 is overexpressed in rheumatoid arthritis and in long-term allogeneic hematopoietic stem cell transplantation survivors; however, decreased expression of AP-1 has been observed in psoriasis, systematic lupus erythematosus and in patients who do not survive after hematopoietic stem cell transplantation. AP-1 also is implicated in the control of various cancer cells. Higher levels of AP-1 components are present in breast and endometrial carcinomas, colorectal cancer and in acute myeloid leukemia, Hodgkin׳s lymphoma and anaplastic large cell lymphoma, with downregulation in ovarian and gastric carcinomas and in patients with chronic myelogenous leukemia. AP-1 may enable the development of helpful markers to identify early-stage disease or to predict severity.

Citations

Feb 6, 2020·Viruses·Kristi L TurtonTrushar R Patel
Nov 14, 2018·Nature Genetics·Salam A AssiConstanze Bonifer
Feb 2, 2019·World Journal of Surgical Oncology·Cheng XiaoZhen Liu
Dec 19, 2019·Frontiers in Immunology·Natalie A ProwAndreas Suhrbier
May 20, 2020·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Jia FengYi Ma
Jun 7, 2019·International Journal of Molecular Sciences·Young Hun LeeSeung-Taek Lee
Aug 31, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Young Yun JungKwang Seok Ahn
Apr 21, 2020·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Christopher J Chermside-ScabboMatthew J Silva
Dec 31, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Rafael Agustín BurgosJuan Hancke
Mar 18, 2021·FEBS Open Bio·Hongwei WuJiansheng Zhu
Apr 3, 2021·Molecular Genetics and Metabolism·Gabriel Rodríguez-GómezAlfonso León-Del-Río
Apr 30, 2019·Biochimica Et Biophysica Acta. Reviews on Cancer·Fabienne BejjaniIsabelle Jariel-Encontre
Oct 15, 2021·Oncogene·Dongqing HuangAmanda G Paulovich

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

The American Journal of the Medical Sciences
Shivtia Trop-Steinberg, Yehudit Azar
Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
Lorentz BrinchIngunn Dybedal
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine
Akira Hiraoka
[Rinshō ketsueki] The Japanese journal of clinical hematology
N Takayama, S Okamoto
© 2022 Meta ULC. All rights reserved